Revolution Medicines’ Daraxonrasib Delivers Landmark Survival Benefit in Phase 3 Pancreatic Cancer Trial
Revolution Medicines has reported what may be one of the most consequential data readouts in pancreatic cancer research in years. Daraxonrasib, the company’s RAS(ON) multi-selective inhibitor, met all primary and secondary endpoints in a registrational Phase 3 trial in patients with KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), nearly doubling median overall survival compared with standard chemotherapy.
A Transformative Efficacy Signal in a Notoriously Difficult Malignancy
Pancreatic cancer carries one of the worst prognoses in oncology. Despite decades of research, durable systemic options have remained elusive, and KRAS mutations, present in approximately 90% of PDAC cases, have historically been considered undruggable. That paradigm began to shift with the advent of KRAS G12C-selective inhibitors, but the broader KRAS-mutant pancreatic cancer population remained underserved.
Daraxonrasib, designed as a RAS(ON) multi-selective inhibitor capable of engaging multiple oncogenic KRAS variants, was developed to address this unmet need at scale.
Phase 3 Efficacy Data
In the Phase 3 trial, daraxonrasib demonstrated a median overall survival of 13.2 months versus 6.7 months in the chemotherapy control arm, representing a hazard ratio that corresponds to approximately a 60% reduction in the risk of death. The magnitude of benefit across both the primary and all pre-specified secondary endpoints positions this as a statistically and clinically meaningful result.
No prior targeted therapy has achieved a survival benefit of this scale in unselected KRAS-mutant PDAC in a randomized Phase 3 setting.
Expedited Path to Regulatory Review
Revolution Medicines has announced plans to pursue an expedited FDA submission, leveraging a Commissioner’s National Priority Review Voucher. This mechanism is expected to accelerate the regulatory timeline and reflects the agency’s recognition of the significant unmet medical need in this patient population.
Competitive and Clinical Context
The Phase 3 readout arrives as the broader RAS inhibitor landscape has grown increasingly competitive, with multiple programs, including pan-RAS degraders, SOS1 inhibitors, and next-generation KRAS G12C agents, advancing through development. Daraxonrasib’s multi-selective RAS(ON) mechanism differentiates it from single-variant approaches and may confer a broader applicability across PDAC’s heterogeneous KRAS mutation spectrum.
If approved, daraxonrasib would represent the first targeted therapy to demonstrate a significant survival benefit in this indication, reshaping the standard of care for one of oncology’s most treatment-resistant diseases.
Read further on Daraxonrasib on OncoDaily.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada